Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Johannes Hankowitz"'
Autor:
Tom Stargardt, Hans-Peter Lipp, Peter J. Kuhlencordt, Thomas-Maria Helms, Dietrich C. Gulba, Johannes Hankowitz, Peter Bramlage, Ingo Ahrens, Sigrid Nikol, Hanno Riess, Andreas Schäfer
Publikováno v:
DMW - Deutsche Medizinische Wochenschrift. 142:986-993
ZusammenfassungMit der kürzlich erfolgten Zulassung des vierten direkten, neuen nicht-Vitamin-K-abhängigen oralen Antikoagulans (NOAK) Edoxaban hat sich die Palette der verfügbaren NOAKs zur Therapie der venösen Thromboembolie (VTE) erweitert. Ku
Autor:
J. C. Geller, Andreas Schäfer, Florian Masuhr, Joachim Weil, Sigmund Silber, Peter Bramlage, Christoph A. Karle, Frederick Palm, Karsten Schrör, Harald Darius, Johannes Hankowitz, Thomas M. Helms, Dietmar Bänsch, Tom Stargardt
Publikováno v:
Herzschrittmachertherapie + Elektrophysiologie. 27:295-306
With the introduction of edoxaban last year in Germany, four nonvitamin K antagonist oral anticoagulants are now available for stroke prevention in patients with nonvalvular atrial fibrillation. These novel oral anticoagulants (NOAC) represent an att
Autor:
Thomas-Maria, Helms, Dietrich, Gulba, Ingo, Ahrens, Andreas, Schäfer, Johannes, Hankowitz, Peter, Kuhlencordt, Hans-Peter, Lipp, Sigrid, Nikol, Hanno, Riess, Tom, Stargardt, Peter, Bramlage
Publikováno v:
Deutsche medizinische Wochenschrift (1946). 142(13)
With the recent approval of the fourth direct non vitamin K dependent oral anticoagulant (NOAC) edoxaban the range of available NOACs for the treatment of venous thromboembolism (VTE) has expanded. Shortly thereafter, two updated guidelines for the p
Autor:
Edelgard Lindhoff-Last, Johannes Hankowitz, Norbert Banik, Johannes Brachmann, Robert Klamroth, Sebastian Schellong, Bernd Pötzsch, Julia Steindl, Pascal M. Dohmen, Katharina Madlener, Stefan Kropff, Markus Michael Müller, Sonja Eberle, Jan Beyer-Westendorf, Marc Schindewolf
Publikováno v:
Journal of the American College of Cardiology. 70(21)
Background Life-threatening heparin-induced thrombocytopenia (HIT) is treated with the alternative nonheparin anticoagulants argatroban, lepirudin, or danaparoid. Frequently, the pentasaccharide fondaparinux is used off-label. Objectives The authors
Publikováno v:
PharmacoEconomics German Research Articles. 11:13-24
Against the background of increasing cost pressure in the German Health Care system German health policy introduced several law changes to increase competition within German health care system for both, payers and health care providers. At the same t
Autor:
Thomas Maria, Helms, Sigmund, Silber, Andreas, Schäfer, Florian, Masuhr, Frederick, Palm, Harald, Darius, Karsten, Schrör, Dietmar, Bänsch, Peter, Bramlage, Johannes, Hankowitz, Christoph A, Karle, Tom, Stargardt, Joachim, Weil, Johann Christoph, Geller
Publikováno v:
HerzschrittmachertherapieElektrophysiologie. 27(3)
With the introduction of edoxaban last year in Germany, four nonvitamin K antagonist oral anticoagulants are now available for stroke prevention in patients with nonvalvular atrial fibrillation. These novel oral anticoagulants (NOAC) represent an att
Prophylaxis, Diagnosis and Therapy of Surgery-Related Complications in Orthopedic and Trauma Surgery
Autor:
Günter Neubauer, Ingo Marzi, Tanja Ulle, Rolf Pauschert, Karin Berger, Johannes Hankowitz, Rupert M. Bauersachs, Kristian Langenberg, Wolfgang Schramm
Publikováno v:
European Journal of Trauma. 31:158-167
Selective factor Xa inhibition by the synthetic pentasaccharide fondaparinux is an efficient way of preventing venous thrombosis. Fondaparinux has been shown to reduce the incidence of venous thromboembolism (VTE) by 50% compared with the low-molecul
Autor:
Katharina Madlener, Pascal M. Dohmen, Sonja Eberle, Jan Beyer-Westendorf, Norbert Banik, Johannes Hankowitz, Stefan Kropff, Edelgard Lindhoff-Last, Marc Schindewolf, Johannes Brachmann, Julia Steindl, Robert Klamroth, Markus Michael Müller, Bernd Pötzsch, Sebastian Schellong
Publikováno v:
Thrombosis research. 134(1)
Introduction In life-threatening immune heparin-induced thrombocytopenia (HIT), treatment with an approved non-heparin anticoagulant is essential. However, off-label use with fondaparinux has been reported in the literature. The study aim was to coll